CompletedNCT00191737
Open-label atomoxetine for ADHD in adolescents
About this title
Read the official source — NCT00191737Medication studyAges 12–17Germany
Understand this study
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Cologne and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 147
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT00191737
- Official title
Show the full official title
An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cologne · Freiburg im Breisgau
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
Listed age limits: 12 years to 17 years.
